Valuation: Vaxart, Inc.

Market Cap 11Cr 9.44Cr 8.81Cr 8.03Cr 15Cr 1.02TCr 15Cr 106.66Cr 41Cr 522.3Cr 40Cr 39Cr 1.68TCr P/E 2026 *
-2.73x
P/E 2027 * -0.51x
Enterprise Value 11Cr 9.44Cr 8.81Cr 8.03Cr 15Cr 1.02TCr 15Cr 106.66Cr 41Cr 522.3Cr 40Cr 39Cr 1.68TCr EV / Sales 2026 *
0.9x
EV / Sales 2027 * 45.2x
Free-Float
98.52%
Yield 2026 *
-
Yield 2027 * -
1 day-0.68%
1 week-3.92%
Current month-2.89%
1 month-11.27%
3 months-31.72%
6 months-28.36%
Current year+26.15%
1 week 0.43
Extreme 0.43
0.47
1 month 0.43
Extreme 0.43
0.52
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
8.13
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 18/03/2024
Chief Tech/Sci/R&D Officer 59 01/03/2024
Director of Finance/CFO - 19/05/2025
Director TitleAgeSince
Director/Board Member 68 21/04/2021
Director/Board Member 76 04/08/2022
Director/Board Member 79 01/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Free

Director

1,18,100 0.0488%
16/07/26 Free

Director

1,18,100 0.0488%
16/07/26 Free

Director

1,18,100 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%-3.92%+20.55%-38.54% 11Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+20.19%+81.44% 5.74TCr
+0.89%-0.63%+2.17%+36.19% 4.76TCr
+0.36%+0.81%+342.39%+742.40% 4.43TCr
-0.96%-4.50%+24.96%+35.38% 4.25TCr
-0.20%-0.77%+4.13%+105.50% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.33%+22.72% 2.85TCr
+0.05%-1.64%-8.14%-11.37% 2.43TCr
Average -0.27%-0.92%+49.43%+111.83% 3.91TCr
Weighted average by Cap. +0.12%-0.84%+56.95%+138.21%

Financials

2026 *2027 *
Net sales 12Cr 11Cr 9.84Cr 8.96Cr 17Cr 1.14TCr 17Cr 119.02Cr 46Cr 582.85Cr 45Cr 44Cr 1.87TCr 23.5L 20.88L 19.49L 17.76L 33.5L 23Cr 33.81L 2.36Cr 91.39L 12Cr 88.23L 86.32L 37Cr
Net income -4.72Cr -4.19Cr -3.91Cr -3.57Cr -6.73Cr -453.75Cr -6.79Cr -47Cr -18Cr -231.96Cr -18Cr -17Cr -744.45Cr -22Cr -20Cr -18Cr -17Cr -32Cr -2.13TCr -32Cr -222.37Cr -86Cr -1.09TCr -83Cr -81Cr -3.49TCr
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
02/26/02 $0.4370 -0.68% 2,39,377
01/26/01 $0.4400 -2.22% 3,39,926
30/26/30 $0.4500 -0.04% 1,61,720
29/26/29 $0.4502 -1.66% 2,97,712
28/26/28 $0.4578 +0.64% 1,24,977
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.4370USD
Average target price
3.333USD
Spread / Average Target
+662.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock